Lundbeck hands over former Alzheimer's candidate to privately-owned biotech company

Lundbeck is giving idalopirdine, which it shelved in 2017 following disappointing results for Alzheimer's disease, to Denovo Biopharma, which has in-licensed rights to all indications.
Photo: Stine Bidstrup/ERH
Photo: Stine Bidstrup/ERH

Denovo Biopharma appears to think that Lundbeck's hand-me-downs are quite the treasure trove.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading